Cited by 1,411Lipoproteins and Cardiovascular HealthLipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk

Open access

Austin, M A, King, M C, Vranizan, K M, Krauss, R M·1990·Circulation

DOI 10.1161/01.cir.82.2.495

Open this paper in CoChat — free account Open PDF

Abstract

In a community-based study of 301 subjects from 61 nuclear families, two distinct phenotypes (denoted A and B) were identified by nondenaturing gradient gel electrophoretic analysis of low density lipoprotein (LDL) subclasses. Phenotype A was characterized by predominance of large, buoyant LDL particles, and phenotype B consisted of a major peak of small, dense LDL particles. Previous analysis of the family data by complex segregation analysis demonstrated that these phenotypes appear to be inherited as a single-gene trait. In the present study, the phenotypes were found to be closely associated with variations in plasma levels of other lipid, lipoprotein, and apolipoprotein measurements. Specifically, phenotype B was associated with increases in plasma levels of triglyceride and apolipoprotein B, with mass of very low and intermediate density lipoproteins, and with decreases in high density lipoprotein (HDL) cholesterol, HDL2 mass, and plasma levels of apolipoprotein A-I. Thus, the proposed genetic locus responsible for LDL subclass phenotypes also results in an atherogenic lipoprotein phenotype.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.cir.82.2.495

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 27,137
Statistical Principles in Experimental Design
Myers, J. L., & Winer, B. J. (1964) · The American Journal of Psychology · doi:10.2307/1419292 · Cited by 8,111
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,895
The Pathogenesis of Atherosclerosis — An Update
Ross, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140806 · Cited by 4,885
Applied linear statistical models : regression, analysis of variance, and experimental designs
Neter, J., Wasserman, W., & Kutner, M. (1974) · Andalas University Repository (Andalas University) · Cited by 2,818
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.256.20.2835 · Cited by 2,512
The analysis of case-control studies
Breslow, N. E., & Day, N. E. (1980) · International Agency for Research on Cancer eBooks · Cited by 2,415

Flagged first, then by citations

Show all 63 references

Research works printed but not linked: 13

Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364
Heiss G, Tyroler HA: Are apolipoproteins useful for evaluat- ing ischemic heart disease? A brief overview of the literature, in Lippel K (ed): Proceeding ofthe Workshop on Apolipoprotein Quantification. National Institutes of Health publication No. (NIH) 83-1266, 1983, pp 7-19
Krauss RM, Lindgren FT, Williams PT, Kelsy SF, Brensike J, Vranizan K, Detre KM, Levy RI: Intermediate density lipo- proteins and coronary artery disease progression in hypercho- lesterolemic men. Lancet 1987;2:62-66
Ernst N, Fisher M, Smith W, Gordon W, Rifkind BM, Little JA, Mishkel MA, Williams DO: The association of plasma high-density lipoprotein cholesterol with dietary intake and alcohol consumption: The Lipid Research Clinics Program Prevalence Study. Circulation: 1980;62:41-52
Lindgren FT, Jensen LC, Hatch FT: The isolation and quan- titative analysis of serum lipoproteins, in Nelson GJ (ed): Blood Lipids and Lipoproteins. New York, Wiley Interscience, 1972, pp 181-274
Morton NE, Rao DC, Lalouel JM: Methods in genetic epi- demiology, in Klingberg MA (ed): Contributions to Epidemiol- ogy and Biostatistics. Basel, Karger, vol 4, 1983, pp 62-102
Snedecor GW, Cochran WG: Statistical Methods, ed 6. Ames, Iowa, Iowa State University Press, 1967
SAS Users Guide: Basics, Version 5 Edition.
SAS User Guide: Statistics, Version 5 Edition.
Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangeiwaia S: Triglyceride and Coronary Heart Disease Mortal- ity. The Lipid Research Clinics Follow-up Study presented at the American Heart Association 27th Conference on Cardio- vascular Disease Epidemiology, Chapel Hill, NC, 1987
Steiner G, Schwartz L, Shumak S, Poapst M: The association of increased levels of intermediate density lipoproteins with smoking and coronary heart disease. Circulation 1987; 75:124-130
Swinkels DW, Demacker PNM, Hendricks JCM, van t'Laar A: Low density lipoprotein subfractions and relationship to other risk factors in healthy individuals. Arteriosclerosis 1989; 9:604-613
Krauss RM, Albers JJ, Brunzell JD: An apolipoprotein B- enriched low density lipoprotein subspecies in familial com- bined hyperlipidemia. Clin Res 1983;31:503a

Sorted by citations

Items 901–1,000 of 1,000

Physiopathologie de la dyslipidémie du syndrome métabolique et du diabète de type 2
Vergès, B. L. (2007) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2007.01.011 · Cited by 10
Apolipoproteins B and A-l as predictors of risk of coronary artery disease
Srinivasan, S. R., & Berenson, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07135-5 · Cited by 10
Evidence based approach for the management of mixed hyperlipidaemia
Gaw, A. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00318-3 · Cited by 10
“A preponderance of small, dense LDL in the LDL profile is associated with a 3–7-fold increased risk of coronary heart disease [3].”
Background
Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients
Takayanagi, N., Onuma, T., Kato, S., Nishiyama, K., Nomiyama, T., & Kawamori, R. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.04.002 · Cited by 10
LDL heterogeneity revisited: lesson for the metabolic syndrome from a new interpopulation study?
Chan, D. C., & Watts, G. F. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01420.x · Cited by 9
Actividad física y enfermedad cardiovascular
Leal, E., Aparicio, D., Luti, Y., Acosta, L., Finol, F., Rojas, E., Toledo, A., Cabrera, M., Bermúdez, V., & Velasco, M. (2009) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 10
Biochemical Basis and Clinical Consequences of Glucolipotoxicity
Srinivasan, V. A. R., Raghavan, V. A., & Parthasarathy, S. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.011 · Cited by 9
The rs2070895 (-250G/A) Single Nucleotide Polymorphism in Hepatic Lipase (HL) Gene and the Risk of Coronary Artery Disease in North Indian Population: A Case-Control Study
Verma, P. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/20496.8378 · Cited by 9
Evaluation of small dense low‐density lipoprotein concentration for predicting the risk of acute coronary syndrome in Chinese population
Wu, B., Yu, Z., Tong, T., Tong, X., Yang, Y., Tang, Y., Ren, H., Liao, Y., & Liao, J. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23085 · Cited by 9
Toward reliable low-density lipoprotein ultrastructure prediction in clinical conditions: A small-angle X-ray scattering study on individuals with normal and high triglyceride serum levels
Jakubauskas, D., Jansen, M., Lyngsø, J., Cheng, Y., Pedersen, J. S., & Cárdenas, M. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102318 · Cited by 9
The Aging Vasculature: Glucose Tolerance, Hypoglycemia and the Role of the Serum Response Factor
Aberdeen, H., Battles, K., Taylor, A., Garner-Donald, J., Davis-Wilson, A., Rogers, B. T., Cavalier, C., & Williams, E. D. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8050058 · Cited by 9
“Moreover, abnormalities in the physical morphology of the lipoprotein particles have also been reported [90].”
Background
PhD Thesis Abstract
(2001) · International Journal of Educational Development · doi:10.1016/s0738-0593(01)00016-5 · Cited by 9
Prevalence and pattern of lipid disorders in Saudi patients with angiographically documented coronary artery disease
Alshehri, A. (2014) · Journal of Family and Community Medicine · doi:10.4103/2230-8229.142970 · Cited by 9
“Many international studies have shown significantly increased risk for CAD in the presence of dyslipidemia.[5-7] However, available information about the prevalence and the pattern of lipid abnormalities in Saudi patients with established coronary atherosclerosis is scarce.”
Effect of infusion of a triacylglycerol emulsion on low-density lipoprotein composition and oxidizability
Callow, J., Samra, J. S., & Frayn, K. N. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00261-x · Cited by 9
“It has also been shown that LDL particle size correlates inversely with the fasting plasma TAG concentration [7].”
Background
Serum Small Dense Low‐density Lipoprotein Concentrations are Elevated in Patients with Significant Coronary Artery Stenosis and are Related to Features of the Metabolic Syndrome
Yazdandoust, S., Parizadeh, S. M. R., Moohebati, M., Yaghmaei, P., Rahsepar, A. A., Tavallaie, S., Soukhtanloo, M., Khojasteh, R., Paydar, R., Fazlinezhad, A., et al. (2012) · Lipids · doi:10.1007/s11745-012-3706-x · Cited by 9
“It has been previously reported that increased plasma triacylglycerol and decreased HDL-C concentrations are usually accompanied by the presence of sd-LDL particles comprising together the atherogenic lipoprotein phenotype [20, 21].”
Background
Significance of small dense low-density lipoproteins as coronary risk factor in diabetic and non-diabetic Korean populations
Yoon, Y., Song, J., Park, H., Park, K. U., & Kim, J. Q. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.076 · Cited by 9
Influence of ApoE Content on Receptor Binding of Large, Buoyant LDL in Subjects With Different LDL Subclass Phenotypes
Barbagallo, C. M., Levine, G. A., Blanche, P. J., Ishida, B. Y., & Krauss, R. M. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.3.466 · Cited by 9
“This accumulation may be due to an increase in their production or greater competition for receptor binding sites due to the increased levels of VLDL and IDL that are found in the plasma of such patients.(40) It may also be that in vivo clearance of these particles is dependent on other receptors whose function may be…”
BackgroundSelf-citation
High Prevalence of C-Reactive Protein Elevation with Normal Triglycerides (100–149mg/dL): Are Triglyceride Levels Below 100mg/dL More Optimal in Coronary Heart Disease Risk Assessment?
Ahmad, I., Zhan, M., & Miller, M. J. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200504000-00002 · Cited by 9
Early-onset type 2 diabetes: higher burden of atherogenic apolipoprotein particles during statin treatment
Song, S. H., & Gray, T. A. (2012) · QJM · doi:10.1093/qjmed/hcs113 · Cited by 9
The effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidism
Minarikova, Z., Gašpar, Ľ., Kružliak, P., Celecová, Z., & Oravec, S. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-158 · Cited by 10
“LDL1 and LDL2 do not fulfil the criteria of atherogenicity for lipoprotein entities which are usually ascribed to LDL lipoproteins.”
BackgroundInfluential
Nutrition, Diet Quality, and Cardiovascular Health
Wang, L., Sikand, G., & Wong, N. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801816-3.00023-6 · Cited by 10
Non-HDL Cholesterol And LDL-C/HDL-C Ratio In Type II Diabetic Patients
Indumati, V., Patil, V. S., Krishnaswamy, D., Satishkumar, D., Viswanathan, V., Mahesh, S., & Rajeshwari, V. A. (2011) · International Journal of Pharma and Bio Sciences · Cited by 9
High-Density Lipoproteins
Francis, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-63438-2.00015-8 · Cited by 12
The Good, The Bad, and The Ugly in Diabetic Diets
Vinik, A. I., & Wing, R. R. (1992) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30217-2 · Cited by 9
Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition
Föger, B., Tröbinger, G., Ritsch, A., Lechleitner, M., Hopferwieser, T., Menzel, H., Utermann, G., Pfeiffer, K. P., & Patsch, J. R. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)05580-p · Cited by 9
Effects of stable fish oil and simvastatin on plasma lipoproteins in patients with hyperlipidemia
Liu, M., Wallmon, A., Wallin, R., & Saldeen, T. G. P. (2003) · Nutrition Research · doi:10.1016/s0271-5317(03)00102-7 · Cited by 9
“Patients with hyperlipidemia run an increased risk of developing coronary heart disease (CHD) [1].”
Background
Factores predictivos del riesgo de enfermedad cardiovascular en los pacientes con diabetes tipo 2 e hipercolesterolemia. Estudio ESODIAH
Pintó, X., Corbella, E., Figueras, R., Biarnés, J., Ricart, W., Morales, C., Falkon, L., & Masana, L. (2007) · Revista Española de Cardiología · doi:10.1157/13100276 · Cited by 9
Relationship between the apolipoprotein E and angiotensin-converting enzyme genotypes and LDL particle size in Japanese subjects
Okumura, K., Matsui, H., Kawakami, K., Numaguchi, Y., Kaneko, S., Morishima, I., Mokuno, S., Toki, Y., & Hayakawa, T. (1999) · Clinica Chimica Acta · doi:10.1016/s0009-8981(99)00108-4 · Cited by 9
Influence of lipoprotein lipids, dietary fat and smoking on macrophage degradation of native and oxidized low density lipoprotein
Regnström, J., Walldius, G., Hådell, K., Johansson, J., Holme, I., OLSSON, A. G., & Nilsson, J. Å. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90063-9 · Cited by 9
New lipoprotein profiles and coronary heart disease. Improving precision of risk.
Nestel, P. J. (1990) · Circulation · doi:10.1161/01.cir.82.2.649 · Cited by 9
Monounsaturated and Marine Ω‐3 Fatty Acids in NIDDM Patientsa
Rivellese, A. A. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb51843.x · Cited by 9
Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension
Kazibwe, R., Jehopio, J., Schaich, C. L., Rikhi, R. R., Mirzai, S., Chevli, P. A., Namutebi, J. H., Chebrolu, S., O'Connor, S., Yeboah, J., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.05.006 · Cited by 12
Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease
Marchioli, R. (2010) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s4743 · Cited by 8
“Austin et al reported the existence of two low-density lipoprotein cholesterol (LDL-C) phenotypic distributions in relation to TG levels, ie, a less atherogenic phenotype A, characterized by large buoyant LDL particles that predominate with low TG levels, and a highly atherogenic phenotype B represented by small dense…”
Influential
Low-density lipoprotein cholesterol/apolipoprotein B ratio is superior to apolipoprotein B alone in the diagnosis of coronary artery calcification
Chang, T.-Y., & Chen, J. (2020) · Coronary Artery Disease · doi:10.1097/mca.0000000000001004 · Cited by 8
Low density lipoprotein subclass distribution in children with diabetes mellitus
Alabakovska, S. B., Labudović, D. D., Tosheska, K., Spiroski, M. Z., & Todorova, B. (2008) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/bf03657031 · Cited by 8
Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype
Dergunov, A. D., Nv, P., Visvikis‐Siest, S., & Siest, G. (2003) · Vascular Pharmacology · doi:10.1016/j.vph.2003.09.002 · Cited by 8
In silico modeling of the dynamics of low density lipoprotein composition via a single plasma sample
Jansen, M., Pfaffelhuber, P., Hoffmann, M. M., Pütz, G., & Winkler, K. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m058446 · Cited by 8
Effects of a sweetpotato protein digest on lipid metabolism in mice administered a high-fat diet
Ishiguro, K., Kurata, R., Shimada, Y., Sameshima, Y., & Kume, T. (2016) · Heliyon · doi:10.1016/j.heliyon.2016.e00201 · Cited by 8
“A relationship between predominance of small, dense LDL particles, high triglyceride levels and low HDL-C concentrations and cardiovascular diseases have been reported (Austin et al., 1990; Campos et al., 1992; Okazaki et al., 2006).”
Background
Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?
Garber, A. J. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00100.x · Cited by 8
Contribution of the atherogenic lipoprotein profile to the development of arterial hypertension
Oravec, S., Dukát, A., Gavorník, P., Čaprnda, M., Kucera, M., & Očadlík, I. (2011) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/bf03657562 · Cited by 8
Lipoprotein disorder in brain infarction and hemorrhage
Sato, A., Asakura, Y., Yokota, C., Suzuki, M., Tsushima, M., Kuriyama, Y., Sawada, T., Yamaguchi, T., Kobayashi, M., & Harano, Y. (1998) · International Journal of Clinical & Laboratory Research · doi:10.1007/s005990050016 · Cited by 8
Analysis of Apolipoproteins
Laker, M. F., & Evans, K. (1996) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456329603300102 · Cited by 8
Biological Importance of Low-Density-Lipoprotein Subfractions
O’Brien, R. C. (1994) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679400100304 · Cited by 8
Factors influencing Lp[a]- particle size as determined by gradient gel electrophoresis.
O'Neal, D. N., Grieve, G. D., Rae, D., Dragicevic, G., & Best, J. D. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39108-2 · Cited by 8
Incidence of lipoprotein lipase genotype for premature termination codon (Ser447-Ter) in Japanese, and association with dyslipoproteinemia
Murano, T., Miyashita, Y., Itoh, Y., Tsuzuki, S., Yamamori, S., Watanabe, H., & Shirai, K. (1998) · Clinica Chimica Acta · doi:10.1016/s0009-8981(98)00084-9 · Cited by 8
Triglycerides
Bazarbashi, N., & Miller, M. J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.006 · Cited by 7
Opinion: Are mental health benefits of the ketogenic diet accompanied by an increased risk of cardiovascular disease?
Diamond, D. M., Mason, P., & Bikman, B. T. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1394610 · Cited by 8
“Thus, the high triglycerides and low HDL of the son provided the basis of the authors’ perspective that the son exhibited LDL subclass pattern B, which is associated with a high risk of CVD and a high carbohydrate diet (75, 76).”
Background
Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9
Quispe, R., Al-Hijji, M. A., Swiger, K. J., Martin, S. S., Elshazly, M. B., Blaha, M. J., Joshi, P. H., Blumenthal, R. S., Sniderman, A. D., Toth, P. P., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.05.005 · Cited by 7
Microchip-based human serum atherogenic lipoprotein profile analysis
Wang, H., Zhang, W., Wan, J., Liu, W.-W., Yu, B., Jin, Q., & Guan, M. (2014) · Analytical Biochemistry · doi:10.1016/j.ab.2014.08.031 · Cited by 7
“An atherogenic lipoprotein phenotype has been shown to consist of three elements that may raise cardiovascular risk: a raised VLDL level, a reduced HDL level, and an abundance of sdLDL [29].”
Background
Distribution of low-density lipoprotein particle size in healthy Korean adult males
Son, J. E., Lee, W., Min, W., Chun, S., Lee, Y.-W., & Park, H. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.042 · Cited by 7
“Phenotype A is characterized by a predominance of large, buoyant LDL particles, and phenotype B is known to have a major peak of small, dense LDL particles (2).”
Background
Separation of the principal HDL subclasses by iodixanol ultracentrifugation
Harman, N., Griffin, B. A., & Davies, I. G. (2013) · Journal of Lipid Research · doi:10.1194/jlr.d037432 · Cited by 7
Plasma LDL subtype distribution in patients with or without coronary stenosis
Öztaş, Y., Özdöl, Ç., & Karaca, L. (2011) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1008-1075 · Cited by 7
“Several studies have reported a 2- to 3-fold increase in coronary heart disease risk among patients with this Sd LDL subtype (9).”
Background
High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.
Cimmino, G., Ciccarelli, G., Morello, A., Ciccarelli, M., & Golino, P. (2015) · Europe PMC (PubMed Central) · Cited by 7
Consenso sobre tratamiento farmacológico de la dislipidemia aterogénica con terapia combinada estatina-fenofibrato
Aterogénica, P. E. D. E. V. E. D. G. D. T. S. D. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.12.001 · Cited by 7
Lower LDL-cholesterol levels associated with increased inflammatory burden in patients with acute ST-segment elevation myocardial infarction
Açıkgöz, E., Açi̇kgöz, S. K., Yaman, B., & Kurtul, A. (2021) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.67.02.20200548 · Cited by 7
Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein ‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Goto, S., Tomoyasu, M., Yamamoto, T., Ohara, M., Terasaki, M., Kushima, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14076 · Cited by 8
“Plasma levels of triglycerides (TG) are the most potent factor determining LDL particle size 9 ; increased TG reduces the mean LDL diameters, and increases the incidence of sdLDL phenotype, pattern B 2 – 4 .”
Background
Effect of Body Mass Index on the Prognostic Value of Atherogenic Index of Plasma in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Kan, Y., Sun, Y., Shen, H., Liu, X., Liu, Y., Shi, D., Ma, X., & Zhou, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206543 · Cited by 7
“…the elevated risk of CAD in individuals with heightened levels of sdLDL compared to those with higher levels of large buoyant LDL (lbLDL) [25,26]. sdLDL is known to be more susceptible to oxidation and the formation of foam cells, rendering it a potential risk factor for atherosclerosis…”
Background
The association of very-low-density lipoprotein with ankle-brachial index in peritoneal dialysis patients with controlled serum low-density lipoprotein cholesterol level
Kanda, E., Ai, M., Okazaki, M., Maeda, Y., Sasaki, S., & Yoshida, M. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-212 · Cited by 7
“There have been two reported routes through which VLDL contributes to the progression of atherosclerosis, namely, through intermediate density lipoprotein (IDL) and small dense LDL [18,22].”
Background
Lipid Disorders in Obesity
Wickramasinghe, M., & Weaver, J. U. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00010-5 · Cited by 7
Risk factors for coronary heart disease in type 1 diabetic children: the influence of apoE phenotype and glycemic regulation
Tso, T. K., Snook, J. T., Lozano, R. A., & Zipf, W. B. (2001) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00312-6 · Cited by 7
Application of electrophoretic techniques to the diagnosis of disorders of lipoprotein metabolism. Examples at the levels of lipoproteins and apolipoproteins
Groß, W., & März, W. (1999) · Analytica Chimica Acta · doi:10.1016/s0003-2670(98)00497-8 · Cited by 7
Host and environmental effects on plasma apolipoprotein B
Jarvik, G. P., Wijsman, E. M., Little, R. E., Albers, J. J., Motulsky, A. G., & Brunzell, J. D. (1993) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02592312 · Cited by 7
Long-term effect of reduced carbohydrate or increased fiber intake on LDL particle size and HDL composition in subjects with type 2 diabetes
Wolever, T. M. S., Tsihlias, E. B., McBurney, M. I., & Le, N. (2003) · Nutrition Research · doi:10.1016/s0271-5317(02)00514-6 · Cited by 7
Cardiovascular complications of diabetes: Prevention and management
Garber, A. J. (2003) · Clinical cornerstone · doi:10.1016/s1098-3597(03)90016-0 · Cited by 7
Ethnic Variation in Insulin Resistance and Risk of Type 2 Diabetes
McKeigue, P. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-716-1_2 · Cited by 7
Treating dyslipidaemia in the patient with type 2 diabetes
Betteridge, D. J. (2004) · European Heart Journal Supplements · doi:10.1016/j.ehjsup.2004.04.001 · Cited by 7
Low‐density lipoprotein subfraction profiles in dialysis patients
Bofinger, A., Westhuyzen, J., Saltissi, D., Morgan, C., & Healy, H. G. (1997) · Nephrology · doi:10.1111/j.1440-1797.1997.tb00211.x · Cited by 7
Ultrasound-monitored laser angioplasty: Preliminary clinical results
Duda, S. H., Huppert, P. E., Kreis, A., Karsch, K. R., & Claussen, C. D. (1993) · CardioVascular and Interventional Radiology · doi:10.1007/bf02602985 · Cited by 7
Modulation of LDL particle size after an oral glucose load is associated with insulin levels
Okumura, K., Matsui, H., Kawakami, K., Morishima, I., Numaguchi, Y., Murase, K., Toki, Y., & Ito, T. (1998) · Clinica Chimica Acta · doi:10.1016/s0009-8981(98)00108-9 · Cited by 7
Do age and baseline LDL cholesterol levels determine the effect of regular exercise on plasma lipoprotein cholesterol and apolipoprotein B levels?
Angelopoulos, T. J., Sivo, S. A., Kyriazis, G. A., Caplan, J. D., Zoeller, R. F., Lowndes, J., Seip, R. L., & Thompson, P. D. (2007) · European Journal of Applied Physiology · doi:10.1007/s00421-007-0537-1 · Cited by 6
Obesity and Metabolic Syndrome in the 21st Century: A Narrative Review of Cardiometabolic Risk and Global Policy Response
Sanchez, D., León, E. M., Salgado, C. N. A., Martinez, Y. S., Figueroa, P. D., Escárcega, M. C., Cohen, A. H., Garcia, X. A. S., Guzman, J. A. R., & Haro, S. E. R. (2025) · Cureus · doi:10.7759/cureus.97204 · Cited by 8
“…et al. demonstrates that small dense LDL particles exhibit greater atherogenic potential than large buoyant LDL because they tend to become oxidized more easily [18], penetrate the arterial intima more efficiently, and have a lower affinity for LDL receptors, prolonging their circulation [19].”
Nonlinear relationship between serum 25-hydroxyvitamin D and lipid profile in Chinese adults
Wang, Q., Miao, X., Hu, M., Xu, F., Tang, G., He, Y., Song, Z., Wan, Z., Xiangjun, N., & Leng, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1388017 · Cited by 6
“Abnormal lipid proﬁle is a characteristic of dyslipidemia and signiﬁcantly increase the susceptibility to cardiovascular disease (6, 7).”
Background
Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia
Jacobson, T. A. (2014) · Clinical Lipidology · doi:10.2217/clp.14.10 · Cited by 6
High fiber and high carbohydrate intake and its association with the metabolic disease using the data of KNHANES 2013 ~ 2017
Moon, H., Ha, K., & Song, Y. (2019) · Journal of Nutrition and Health · doi:10.4163/jnh.2019.52.6.540 · Cited by 6
“또한 HDL-콜레스 테롤이 남자 40 mg/dl 미만, 여자 50mg/dl 미만이면서, 중 성지방이 150 mg/dl 이상일 경우 죽상경화성 이상지질혈 증 (atherogenic dyslipidemia)으로 진단하였다 [14].”
Lipoprotein Metabolism and Atherogenesis
Shepherd, J., & Packard, C. J. (2000) · Springer eBooks · doi:10.1007/978-4-431-68424-4_1 · Cited by 6
Add-on Ezetimibe Reduces Small Dense Low-Density Lipoprotein Cholesterol Levels Without Affecting Absorption of Eicosapentaenoic Acid in Patients with Coronary Artery Disease: A Pilot Study
Kubo, M., Miyoshi, T., Kimura, T., Noda, Y., Kohno, K., Nakamura, K., Morita, H., & Ito, H. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0082-3 · Cited by 6
Higher levels of serum triglyceride and dietary carbohydrate intake are associated with smaller LDL particle size in healthy Korean women
Kim, O. Y., Chung, H. K., & Shin, M. (2012) · Nutrition Research and Practice · doi:10.4162/nrp.2012.6.2.120 · Cited by 6
“[6], subjects with a LDL profile dominated by sd-LDL have a three-fold increased CVD risk.”
Background
Diabetes mellitus, but not small dense low‐density lipoprotein, is predictive of cardiovascular disease: A K orean community‐based prospective cohort study
Suh, S., Park, H., Jin, S., Kim, H. J., Bae, J. C., Park, S. Y., Park, M. K., Kim, D. K., Cho, N. H., & Lee, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12091 · Cited by 6
Developing computational model-based diagnostics to analyse clinical chemistry data
van Schalkwijk, D. B., van Bochove, K., van Ommen, B., Freidig, A. P., van Someren, E. P., van der Greef, J., & de Graaf, A. A. (2010) · Briefings in Bioinformatics · doi:10.1093/bib/bbp071 · Cited by 8
“This measured information is likely to be relevant, because several aspects of the lipoprotein phenotype are known to contribute to cardiovascular risk together, in a so-called ‘Atherogenic Lipoprotein Phenotype’ [37].”
Background
Switching from atorvastatin to rosuvastatin lowers small, dense low-density lipoprotein cholesterol levels in Japanese hypercholesterolemic patients with type 2 diabetes mellitus.
Bando, Y., Toyama, H., Kanehara, H., Hisada, A., Okafuji, K., Toya, D., & Tanaka, N. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.013 · Cited by 7
“[5] Austin MA, King MC, Viranizan KM, Krauss RM.”
Background
GC-MS Analysis of Phytochemicals and Hypoglycemic Effect of Catharanthus roseus in Alloxan-Induced Diabetic Rats
Anand, T., Priyadharshini, G. S., & Balamurugan, V. (2015) · Cited by 6
American Diabetes Association Annual Meeting, 1999
Bloomgarden, Z. T. (2000) · Cited by 6
Novel Risk Stratification Assays for Acute Coronary Syndrome
Ahmed, H. M., & Hazen, S. L. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0880-8 · Cited by 7
Association of Paraoxonase-1 L55M and Q192R Polymorphisms with Pcos Risk and Potential Risk Factors for Atherosclerosis
Nalkıran, H. S., Şahin, S. B., Ayaz, T., Nalkıran, İ., Güzel, A. İ., Eldeş, T., & Yıldız, Y. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0271 · Cited by 6
Dyslipidaemias and their treatment in high complexity centres in Colombia
Ruiz, Á. J., Vargas‐Uricoechea, H., Urina‐Triana, M., Román-Gonzaléz, A., Isaza, D., Etayo, E., Quintero, A. E., Molina, D. I., Toro, J. M., Parra, G., et al. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.05.001 · Cited by 6
Cyclosporine A induces cardiac remodeling through TGF-β/Smad3/miR-29 signaling pathway and alters gene expression of miR-30b-5p/CaMKIIδ isoforms pathways: alleviating effects of moderate exercise
Nourmohammadi, K., Bayrami, A., Naderi, R., & Shirpoor, A. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08506-1 · Cited by 6
“It is reported that the risk of cardiac disease increases threefold by LDL due to its composition and size [21].”
Background
State of the Science on Cardiometabolic Risk After Spinal Cord Injury: Recap of the 2013 ASIA Pre-Conference on Cardiometabolic Disease
Schladen, M. M., & Groah, S. L. (2014) · Topics in Spinal Cord Injury Rehabilitation · doi:10.1310/sci2002-105 · Cited by 6
Atherosclerosis, Introduction and Pathophysiology
Yahagi, K., Davis, H. R., Joner, M., & Virmani, R. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_25 · Cited by 6
Dyslipidemia: Genetics and Role in the Metabolic Syndrome
Nora, L., & Pillai, A. L. P. C. (2012) · InTech eBooks · doi:10.5772/28188 · Cited by 7
“…formed, which have a lower affinity for the LDL receptor (LDLR), more susceptibility to oxidation and a higher affinity for macrophages; and, thus, sdLDL particles contribute to the atherosclerotic process (Austin et al., 1990; Littlewood and Bennett, 2003) and likely MetSyn (Kruit et al., 2010).”
Background
Preventing, stopping, or reversing coronary artery disease— triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment
Ferguson, E. E. (2000) · Disease-a-Month · doi:10.1016/s0011-5029(00)90011-7 · Cited by 6
Physical exercise in dyslipoproteinemias: An update
Berg, A., König, D., Halle, M., & Baumstark, M. W. (2002) · European Journal of Sport Science · doi:10.1080/17461390200072403 · Cited by 6
“Today an atherogenic lipoprotein profile is defined as a lipid constellation of elevated serum cholesterol, triglycerides, LDL cholesterol, particularly small dense LDL particles and reduced HDL, in particular HDL2 subfraction particles (3, 30).”
Background
Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension
Ryomoto, K., Suzuki, M., Kanazawa, A., Hasegawa, M., Kimura, Y., Yamamura, T., & Harano, Y. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00256-3 · Cited by 6
Cardiovascular risks in obesity
Uchegbu, E., & Kopelman, P. G. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03344056 · Cited by 6
Dyslipidemia and Cardiovascular Risk in Diabetes
Carmena, R., & Ascaso, J. F. (2003) · Springer eBooks · doi:10.1007/978-3-642-59352-9_7 · Cited by 6
New targets for lipid lowering and atherosclerosis prevention
Sirtori, C. R. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00024-0 · Cited by 6
The Mediterranean Diet and Coronary Heart Disease
Matalas, A.-L., Zampelas, A., & Stavrinos, V. (2001) · CRC Press eBooks · doi:10.1201/9781420042221-14 · Cited by 6
Prevention and Regression of Atherosclerosis: Effects of Hmg-CoA Reductase Inhibitors
Bjelajac, A., Goo, A. K., & Weart, C. W. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603001116 · Cited by 6
Determinants of Low-Density Lipoprotein Particle Diameter during Antiretroviral Therapy Including Protease Inhibitors in HIV-1-Infected Patients
Bittar, R., Giral, P., Aslangul, E., Assoumou, L., Valantin, M., Kalmykova, O., Fesel-Fouquier, V., Costagliola, D. G., Bonnefont‐Rousselot, D., & the ANRS 126 study group (2012) · Antiviral Therapy · doi:10.3851/imp2065 · Cited by 6
Cardiovascular Disease
Schulte, P. A., Rothman, N., & Austin, M. A. (1993) · Elsevier eBooks · doi:10.1016/b978-0-12-632345-0.50017-1 · Cited by 6
Self-citation
Untitled work
Laffel (1999) · doi:10.1002/(sici)1520-7560(199911/12)15:6

Authors: Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M.
Affiliations: University of California, Berkeley (US)
ORCID: King, M C
Krauss, R M
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1990-08
Volume: 82
Issue: 2
Pages: 495-506
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.82.2.495
OpenAlex: W2089286420
Cited by: 1,411
References: 63
Citations by year: 2026: 11 · 2025: 15 · 2024: 17 · 2023: 39 · 2022: 20 · 2021: 26 · 2020: 25 · 2019: 27 · 2018: 17 · 2017: 21 · 2016: 27 · 2015: 42 · 2014: 38 · 2013: 46 · 2012: 39
FWCI: 47.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Energy (DE-AC03-?, AC03-76SF00098, DEAC03-76SF00098)
National Institutes of Health (7r29hl038760-03, 5p01hl018574-26, DE-AC03- 76SF00098)
National Heart, Lung, and Blood Institute (HL38760, HL-18574)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: atherogenic lipoprotein phenotype, LDL subclasses, low-density lipoprotein, coronary heart disease risk, genetic markers, single-gene inheritance, apolipoprotein B, apolipoprotein A-I, HDL cholesterol, HDL2, triglycerides, VLDL, intermediate density lipoprotein
MeSH terms: Adolescent, Adult, Aged, Arteriosclerosis, Child, Child, Preschool, Chromosome Mapping, Coronary Disease, Female, Genetic Markers, Humans, Lipids, Lipoproteins, Cholesterol, HDL, Male, Middle Aged, Phenotype, Risk Factors, Triglycerides, Multivariate Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks